BioSpace News Archive

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported interim data from the Company’s ongoing, open label clinical trial of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism (SD), the two most common forms of chronic inducible urticaria (CIndU)

– Matinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics – – Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021 – –

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2021 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, April 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, reported its full year 2020 operating and financial results.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Science 37, the industry’s only Decentralized Clinical Trial Operating System™, today announced a strategic partnership to enable enhanced decentralized clinical trial delivery.

Bio-Techne Corporation (NASDAQ: TECH) today announced the release of Cultrex™ UltiMatrix™ Reduced Growth Factor Basement Membrane Extract (RGF BME), an extracellular matrix hydrogel that provides significant performance and consistency benefits for culturing organoids and pluripotent stem cells.

Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19 Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study

Health Advance, Inc www.HealthAdvanceGroup.com reports that the company’s application to OTC Markets OTCIQ News and Information Service has been approved, and fees paid, for the purpose of commencing Current Information filings under OTC Markets’ Alternative Reporting Guidelines.

Automation solution increases processing capacity to 6,000 PCR tests per day, expandable to 12,000 daily tests with minor upgrades